Selinexor plus Ruxolitinib Reduces Spleen Volume, but Does Not Improve Symptom Responses Over Ruxolitinib in Patients with JAK Inhibitor-Naïve Myelofibrosis By Ogkologos - June 18, 2026 121 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SENTRY study Source RELATED ARTICLESMORE FROM AUTHOR Enzalutamide Continues to Provide Substantial Long-Term OS Benefit at 8 Years for Patients with Metastatic Hormone-Sensitive Prostate Cancer Metastatic Breast Cancer: ESMO Living Guideline EMA Recommends Extension of Indications for Datopotamab Deruxtecan MOST POPULAR Efficacy and Safety of Elranatamab, BCMA-CD3 Bispecific Antibody, in Patients with... August 28, 2023 ¿Tener paneles solares o vivir cerca de una granja solar puede... April 6, 2023 EMA Recommends Granting a Marketing Authorisation for Generic Nilotinib August 16, 2024 Cómo mi diagnóstico de cáncer a los 17 años cambió mi... December 14, 2020 Load more HOT NEWS GD2-CART01 May Induce Sustained Antitumour Effect in a Proportion of Patients... As Winter Storms Plague Southern States, GreaterGood Is Helping Where It’s... Promising pCR Rates with Neoadjuvant Durvalumab Plus Platinum-based Chemotherapy Combined with... Tumour-Infiltrating Clonal Haematopoiesis Increases the Risk of Recurrence or Death Among...
